Cytogen, a precision medical bio company, and Mantiz, a spinal implant manufacturing company, have signed a domestic distribution agreement covering Mantiz’ full spinal implant portfolio. The agreement was signed on the 27th and formalizes a mid- to long-term strategic partnership between the two companies.
The contract goes beyond a traditional product-specific distribution arrangement. Rather than focusing on a single technology or implant, the partnership establishes a framework for jointly expanding a portfolio of spinal implants and biomedical devices, including next-generation patient-specific solutions based on 3D printing technologies. Under the agreement, Cytogen will also build a domestic distribution system for all existing spinal implants developed by Mantiz.
Mantiz has already demonstrated technological reliability and clinical stability at major university hospitals and specialized spine centers across Korea. Its portfolio includes the vertebral screw system QUATTRO, the 3D printing-based implant PANTER-S, and the patient-customized 3D CAGE CUSFIT, positioning the company as a first mover in the application of additive manufacturing and customization in spinal implants.
Through this partnership, Cytogen will take responsibility for domestic sales and distribution of Mantiz’ flagship spinal implant products. Over time, the scope of collaboration will expand to include Mantiz’ broader biomedical device portfolio, such as wound covering materials, surgical films, absorbent hemostatic agents, and next-generation customized 3D spinal implants. Cytogen expects this strategy to provide a stable revenue base while enabling expansion into higher value-added regenerative and precision medical businesses, strengthening its long-term growth engine.
“This agreement represents a strategic choice aimed at building a stable profit structure and securing early leadership in the next-generation medical device market, rather than functioning as a simple distribution agency,” said Lee Hoon-sung, Head of Cytogen’s M&A Business Division. “By combining Cytogen’s execution capabilities in sales and distribution with Mantiz’ proven technology, we aim to deliver both tangible clinical value and sustainable business outcomes in spinal treatment. In the mid to long term, we plan to expand across regenerative and biomedical devices to complete a precision medical-based bio portfolio.”
Kim Eui-joon, CEO of Mantiz, described the partnership as a key inflection point for the company. “Our collaboration with Cytogen is a strategic turning point that enables us to expand the next-generation customized implant market while maintaining stable growth in the existing spinal implant segment,” he said. “We also plan to gradually extend our influence from the domestic market to global markets.”
Through this agreement, Cytogen and Mantiz is aim to reinforce their competitive position in the spinal implant market, strengthen their presence in next-generation customized solutions, and broaden cooperation across regenerative and biomedical device sectors, pursuing a long-term growth roadmap as a precision medical-based bio platform.
About Cytogen
CytoGen, Inc. is a Circulating Tumor Cell (CTC) based Liquid Biopsy Platform company. We save lives and present relief enabling precision medicine, monitoring prognosis, early diagnosis assistance. The Liquid Biopsy Platform Smart Biopsy™ captures, stains, analyzes live CTC in the blood. – Smart Biopsy™ Cell Isolator CIS 030 – Smart Biopsy™ IF Stainer CST 030 – Smart Biopsy™ Cell Image Analyzer CIA 040 Our services are available at headquarters in Seoul, ExperTox CLIA Lab in Texas, CEPM branch in New York.Website: http://www.cytogenlab.com/
About Mantiz
Founded in 2015, Mantiz specializes in developing and manufacturing spinal implants, bio-friendly medical devices, and veterinary solutions. Based in Daegu’s medical cluster, we actively collaborate with top institutions like K-MEDIhub, Daegu TP, Kyungpook National University, and Yeungnam University, as well as medical professionals from hospitals across Korea, to drive continuous R&D and innovation. Our expertise spans: Bio: High-performance hemostatic agents and wound care solutions using natural, biocompatible ingredients. Veterinary: Advanced solutions for animal bleeding control and wound care, offering a range of formulas made from bio-friendly, natural components. Spine: Patented spinal implants and Korea’s first 3D Printed Interbody Fusion Cage, supported by extensive clinical data and a robust sales network. Cosmetic: Bio-friendly skincare solutions developed with expertise in medical wound care. Mantiz is committed to delivering innovative technology and superior products through collaboration with leading experts and institutions, advancing healthcare solutions worldwide. https://mantiz.net
Source: https://www.mk.co.kr